6-methyl-N-[4-methyl-5-[(3-methylpiperidin-1-yl)methyl]thiophen-2-yl]-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-amine | 1094206-08-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 英文名称: 6-methyl-N-[4-methyl-5-[(3-methylpiperidin-1-yl)methyl]thiophen-2-yl]-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-amine
• CAS: 1094206-08-2
• 化学式: C₂₂H₂₇N₇S
• 分子量: 421.569
• InChiKey: KZMUJEHNGUYESP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 6-methyl-N-[4-methyl-5-[(3-methylpiperidin-1-yl)methyl]thiophen-2-yl]-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-amine
  参考文献：
  名称：

  Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors

  摘要：

  Our continued effort toward the development of the imidazo[1,2-a] pyrazine scaffold as Aurora kinase inhibitors is described. Bioisosteric approach was applied to optimize the 8-position of the core. Several new potent Aurora A/B dual inhibitors, such as 25k and 25l, were identified. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.008

文献信息

• [EN] IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS<br/>[FR] IMIDAZOPYRAZINES COMME INHIBITEURS DE LA PROTÉINE KINASE
  申请人：SCHERING CORP

  公开号：WO2008156614A2

  公开（公告）日：2008-12-24

  [EN] In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions.
  [FR] Dans ses nombreux modes de réalisation, la présente invention porte sur une nouvelle classe de composés imidazopyrazine comme inhibiteurs de protéine et/ou d'Aurora kinases, sur des procédés de préparation de ces composés, sur des compositions pharmaceutiques comprenant un ou plusieurs de ces composés, sur des procédés de préparation de formulations pharmaceutiques comprenant un ou plusieurs de ces composés et sur des procédés de traitement, de prévention, d'inhibition ou d'amélioration d'une ou plusieurs maladies associées aux protéines ou Aurora kinases à l'aide de ces composés et de ces compositions pharmaceutiques.
• Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors
  作者：Zhaoyang Meng、Bheemashankar A. Kulkarni、Angela D. Kerekes、Amit K. Mandal、Sara J. Esposite、David B. Belanger、Panduranga Adulla Reddy、Andrea D. Basso、Seema Tevar、Kimberly Gray、Jennifer Jones、Elizabeth B. Smith、Ronald J. Doll、M. Arshad Siddiqui

  DOI：10.1016/j.bmcl.2010.10.008

  日期：2011.1

  Our continued effort toward the development of the imidazo[1,2-a] pyrazine scaffold as Aurora kinase inhibitors is described. Bioisosteric approach was applied to optimize the 8-position of the core. Several new potent Aurora A/B dual inhibitors, such as 25k and 25l, were identified. (C) 2010 Elsevier Ltd. All rights reserved.